🛰️ Daily AI Frontier
‹ back to 2026-07-16

Modular in vivo antibody–ADC click to reverse drug resistance in tumours

Research Other

Merged summary

TL;DR — This is a biomedical/chemistry paper on in vivo bioorthogonal "click" ligation of therapeutic antibodies to antibody–drug conjugates (ADCs) to boost antitumor activity in resistant tumors; it is not AI-advancement material, so none of the AI topics apply.

  • Reports a modular strategy that links clinically used therapeutic antibodies to ADCs directly in the body via bioorthogonal click chemistry.
  • Claims enhanced antitumor activity in heterogeneous and treatment-resistant tumors, aimed at reversing drug resistance.
  • Content is thin (title + abstract snippet only); no AI/ML methods, models, or computational results are described, hence "Other."

Sources (1)

Modular in vivo antibody–ADC click to reverse drug resistance in tumours

Nature Cristina Simó, Alexander C. Vanover, Ricardo D’Oliveira Albanus, Sandeep Surendra Panikar, Shayla Shmuel, Alex Benton, Jader Giraldo-Guzman, José M. Luna, Yifei Xu, Na-Keysha Berry, Nai Keltee, Jingxia Liu, Farrokh Dehdashti, Patrícia M. R. Pereira 2026-07-15 doi:10.1038/s41586-026-10789-w

TL;DR — This is a biomedical/chemistry paper on in vivo bioorthogonal "click" ligation of therapeutic antibodies to antibody–drug conjugates (ADCs) to boost antitumor activity in resistant tumors; it is not AI-advancement material, so none of the AI topics apply.

  • Reports a modular strategy that links clinically used therapeutic antibodies to ADCs directly in the body via bioorthogonal click chemistry.
  • Claims enhanced antitumor activity in heterogeneous and treatment-resistant tumors, aimed at reversing drug resistance.
  • Content is thin (title + abstract snippet only); no AI/ML methods, models, or computational results are described, hence "Other."
item →